The higher sensitivity of neoplastic cells with high HER2 expression to IFN may have clinical implications as it suggests the benefits of anti-HER2 conjugated IFN-β in patients with high-risk HER2-positive cancer. The gene discussed is IFNB1; the disease is cancer.